Exact Sciences Corporation (NASDAQ:EXAS) – Investment analysts at Craig Hallum lifted their Q3 2017 EPS estimates for shares of Exact Sciences Corporation in a report released on Thursday. Craig Hallum analyst B. Bonello now forecasts that the medical research company will post earnings per share of ($0.35) for the quarter, up from their previous estimate of ($0.38). Craig Hallum also issued estimates for Exact Sciences Corporation’s Q4 2017 earnings at ($0.36) EPS, FY2017 earnings at ($1.41) EPS, Q1 2018 earnings at ($0.33) EPS, Q2 2018 earnings at ($0.33) EPS and FY2018 earnings at ($1.28) EPS.

EXAS has been the subject of several other research reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of Exact Sciences Corporation in a research report on Wednesday, April 26th. Cowen and Company upped their price objective on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, May 15th. Leerink Swann set a $38.00 price objective on shares of Exact Sciences Corporation and gave the stock a “buy” rating in a research report on Friday, April 28th. Vetr cut shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 target price for the company. in a report on Thursday, July 6th. Finally, Roth Capital reissued a “buy” rating and issued a $40.00 target price (up previously from $33.00) on shares of Exact Sciences Corporation in a report on Thursday, June 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. Exact Sciences Corporation has a consensus rating of “Buy” and a consensus price target of $33.75.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/07/q3-2017-eps-estimates-for-exact-sciences-corporation-boosted-by-analyst-exas-updated-updated-updated.html.

Exact Sciences Corporation (NASDAQ:EXAS) opened at 37.93 on Monday. The company’s market capitalization is $4.22 billion. The company’s 50-day moving average is $33.86 and its 200 day moving average is $24.14. Exact Sciences Corporation has a one year low of $11.94 and a one year high of $38.92.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Thursday, April 27th. The medical research company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. Exact Sciences Corporation had a negative net margin of 116.39% and a negative return on equity of 49.24%. The firm had revenue of $48.36 million during the quarter, compared to the consensus estimate of $37.38 million. During the same period last year, the firm posted ($0.49) EPS. The firm’s quarterly revenue was up 225.9% on a year-over-year basis.

Hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. purchased a new stake in Exact Sciences Corporation during the fourth quarter worth $192,000. Botty Investors LLC purchased a new stake in Exact Sciences Corporation during the first quarter worth $200,000. Eqis Capital Management Inc. purchased a new stake in Exact Sciences Corporation during the first quarter worth $201,000. Teacher Retirement System of Texas purchased a new stake in Exact Sciences Corporation during the first quarter worth $203,000. Finally, Ameritas Investment Partners Inc. increased its stake in Exact Sciences Corporation by 455.0% in the first quarter. Ameritas Investment Partners Inc. now owns 9,129 shares of the medical research company’s stock worth $216,000 after buying an additional 7,484 shares in the last quarter. 84.96% of the stock is owned by institutional investors and hedge funds.

In other Exact Sciences Corporation news, SVP D Scott Coward sold 1,987 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total transaction of $69,962.27. Following the completion of the sale, the senior vice president now owns 57,603 shares of the company’s stock, valued at approximately $2,028,201.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.00% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History and Estimates for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.